SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug ...
Sellas Life Sciences (NASDAQ:SLS) shares jumped as much as 13% premarket on Thursday after the biopharmaceutical company and partner GenFleet Therapeutics disclosed yet another regulatory milestone ...
SHANGHAI, Jan. 11, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug ...
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
The Food and Drug Administration has granted an Orphan Drug Designation to SLS009, a CDK9 inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphomas. The Food and ...
SHANGHAI, Dec. 10, 2023 /PRNewswire/ -- Dizal today presented the full analysis of the multinational pivotal study of golidocitinib for r/r PTCL (JACKPOT8 PART B) in an oral presentation at the 65th ...
ORLANDO — There is an urgent need for new therapies to treat relapsed or refractory peripheral T-cell lymphoma, but results of a phase 2 study suggest that monotherapy with the immune checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results